Latest News - Danaher
Top Corporates Hub
Danaher
The Value Traps Of The REIT Sector
27.12.2025 08:50
Discover which low-priced REITs are value traps and learn how to avoid bad investments in 2026. Click for my pick of stocks to avoid in the sector.
3 Mid-Cap Stocks We Find Risky
15.12.2025 04:33
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
Lateral Flow Assay Components Market to Hit USD 486.2 Million by 2030: Rising Prevalence of Infectious Diseases Drives Growth
12.12.2025 09:04
The global lateral flow assay (LFA) components market is poised for significant growth, projected to reach USD 486.2 million by 2030 from USD 392.4 million in 2025, with a CAGR of 4.4%. This expansion is driven by rising infectious diseases, demand for point-of-care testing, and home-based diagnostics. Sandwich assays dominate due to their high sensitivity and specificity in clinical settings. Medical device manufacturers lead market demand, while contract manufacturers grow, especially in Asia-
Is Danaher Stock Still Attractive After Its Recent 9.1% Price Jump?
11.12.2025 00:16
If you have been wondering whether Danaher at around $230 a share is a bargain in disguise or a quality name priced for perfection, you are not alone. This breakdown is designed to give you a clear, calm answer. Over the last month the stock has climbed about 9.1%, even though it is only up 0.3% year to date and is still roughly flat over three years. This tells us sentiment has shifted recently even if long term returns have been muted. That renewed interest has come as investors refocus on...
Jim Cramer Says “Danaher’s Been Acting Much Better”
04.12.2025 05:05
Danaher Corporation (NYSE:DHR) is one of the stocks Jim Cramer recently discussed. Cramer noted that he still likes the stock for the Charitable Trust, as he said: “Now, first, there’s tried and true, but lately trying Danaher, DHR, a conglomerate that became more focused on life sciences diagnostics when it spun off its water and […]
Danaher (DHR) Q3 2025 Earnings Call Transcript
28.11.2025 00:19
With us today are Rainer Blair, our President and Chief Executive Officer; and Matt McGrew, our Executive Vice President and Chief Financial Officer. And with that, I'd like to turn the call over to Rainer.
Human Papilloma Virus (HPV) Test and Pap Smear/Test Market Research and Forecast Report 2025-2030, Competitive Analysis of Market leaders - Hologic, BD, Roche, QIAGEN, and Danaher
18.11.2025 11:53
The HPV testing and Pap test market is set to grow from USD 2.44 billion in 2025 to USD 3.94 billion by 2030, with a CAGR of 10.0%. This growth is fueled by increased awareness of cervical cancer and government-led screening initiatives. Consumables lead the market, driven by demand for reagents and collection kits essential for testing. While cervical cancer screening dominates, vaginal cancer screening is poised for rapid growth, aided by enhanced diagnostic capabilities. The Asia Pacific regi
Danaher Corporation (DHR) Presents at Jefferies London Healthcare Conference 2025 Transcript
18.11.2025 08:28
Danaher Corporation (DHR) Jefferies London Healthcare Conference 2025 November 18, 2025 6:00 AM ESTCompany ParticipantsRainer Blair - President, CEO &...
Jim Cramer Says BillionToOne Has a “Fantastic Story” Within the Diagnostics Space
18.11.2025 05:34
BillionToOne, Inc. (NASDAQ:BLLN) is one of the stocks Jim Cramer expressed his thoughts on. Cramer noted that he is a “big fan” of the industry the company is a part of, as he stated: “Where do I come down on this thing? Honestly, I really like it. BillionToOne is playing in an industry that I’m […]
Biopsy Devices Market: Key Players Analysis Recent Developments, Company Strategies, Sustainability Benchmarking, Product Launches, Key Persons, and Revenue Forecasts
10.11.2025 14:17
The Biopsy Devices market is projected to reach $4.02 billion by 2033, growing from $2.43 billion in 2024 at a CAGR of 5.75%. This growth is driven by personalized care demand, rising cancer cases, and minimally invasive treatments enhancing patient comfort. Key biopsy devices include needle, punch, and surgical tools for various medical needs. Advancements in biopsy technology ensure precise, early cancer detection and improved patient outcomes. Leading companies like Cardinal Health, Hologic,
Tala Health raises $100 million seed round, as Ritankar Das seeks to build a holding company for the AI era
04.11.2025 09:26
Titan Holdings has launched a new operating company, Tala Health, Fortune has exclusively learned.
5 Must-Read Analyst Questions From Danaher’s Q3 Earnings Call
28.10.2025 05:34
Danaher’s third quarter was marked by solid execution across its core businesses, with management citing bioprocessing momentum and a stronger-than-anticipated performance in respiratory diagnostics as key drivers. CEO Rainer Blair highlighted that demand for monoclonal antibody production remained robust, propelling bioprocessing growth, while Cepheid’s respiratory testing revenues benefited from customers ordering earlier than usual. Management also pointed to disciplined cost management and o
Unlocking Danaher (DHR) International Revenues: Trends, Surprises, and Prospects
27.10.2025 13:15
Explore Danaher's (DHR) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Why Analysts See the Danaher Story Shifting Amid Mixed Signals and Evolving Growth Forecasts
22.10.2025 20:12
Danaher's stock has seen its Fair Value Estimate increase to $247.30 from $244.50, even as growth projections become more mixed across the industry. Recent analyst commentary shows a split between optimism about stabilization within key segments and caution about the pace of recovery ahead. Stay tuned to learn how you can keep up with the evolving Danaher story as market views continue to shift. What Wall Street Has Been Saying ? Bullish Takeaways BofA continues to rate Danaher as a Buy,...
Danaher (DHR) Jumps on Improved Q3 Earnings
22.10.2025 18:48
We recently published 10 Stocks Leaving Wall Street in the Dust. Danaher Corp. (NYSE:DHR) is one of the best performers on Tuesday. Danaher bounced back by 5.94 percent on Tuesday to close at $220.77 apiece after achieving an improved earnings performance in the third quarter of the year. In an updated report, Danaher Corp. (NYSE:DHR) […]
Danaher: Regaining Growth Momentum
22.10.2025 10:49
Discover Danaher's strong Q3 results, strategic reinvestments, and biotech growth. See why DHR is poised for future earnings expansion.